Depressive disorders occur twice as often in women compared with men. 11

Marlene Freeman, MD

Associate Professor of Psychiatry, Harvard Medical School
Director of Clinical Services, Perinatal and Reproductive Psychiatry Program,
Massachusetts General Hospital

?

"Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods"

Frontiers in Neuroscience

Max Planck Institute for Human Cognitive and Brain Sciences



TREATMENT INNOVATIONS IN WOMEN'S MENTAL HEALTH

Women of All Ages and their HCPs Desire Treatment Options Designed to Address their Unique Mental Health Needs Effectively and Safely

EnBrace HR small soft gel

All-Natural & Safe Ingredients Root Cause Treatment

Clinically Proven Effectiveness for:


Major Depressive Disorder PMS/PMDD & Menopause Including in and around pregnancy

INTERACTIONS BETWEEN SEX HORMONES AND NEUROTRANSMITTERS

Frontiers in Neuroscience/Neuroendocrine Science, February 2015/Volume 9/Article 37/ Page 4

Interaction between ovarian hormone levels, receptor sites, and circuits, modulate serotonergic functions, levels, and reactivity in females throughout adolescence and adulthood - Affecting mood, memory, emotions, appetite, and cognition.

Serotonergic Pathways



"Promising therapeutic approaches to improve PMS, PMDD, Perimenopausal mood and depressive disorders should include a strategy that increases neurotransmitters by administering dietary coenzymes and mineral cofactors that are the precursors for the monoamines metabolized by MAO-A."

EnBrace HR Small Gel Cap

INGREDIENTS


Rx | All Natural | Unique | Bioactive Coenzyme Vitamin Gel Cap

"EnBrace HR contains 5.53 mg. of L-Methylfolate Magnesium and small quantities of other folate derivatives (Img. folic acid and 2.5mg of folinic acid) optimal for a depressed population with high rates of MTHFR polymorphism that affect folic acid metabolism and high risk of neural tube defects and other birth defects."

Freeman M. et al: A prenatal Supplement with Methylfolate for the Treatment and Prevention of Depression in Women Trying to Conceive and During Pregnancy, Annals of Clinical Psychiatry, February 2019.

L-Methylfolate Magnesium	5.53mg
Folinic Acid	2.5mg
Folic Acid	lmg
B12 (Methylcobalamin)	25mcg
B12 (Adenosylcobalamin)	25mcg
B6 (Pyridoxal-5-Phosphate)	25mcg
B1 (Thiamine Pyrophosphate)	25mcg
B2 (Flavin Adenine Dinucleotide)	25mcg
B3 (Nicotinamide Adenine Dinucleotide)	25mcg
PS-Omega-3 (Phosphatidylserine, EPA, DHA)	23mg
Magnesium Ascorbate	24mg
Magnesium L-Threonate	lmg
Iron (Ferrous Glycine Cysteinate)	13.6mg
Zinc Ascorbate	lmg
Betaine	500mcg
Citric Acid Monohydrate	1.83mg
Sodium Citrate	3.67mg
CoQ10	500mcg
Bioperine (B Vitamin Bioenhancer)	25mg

METHYLATION CHART



CLINCAL STUDY OVERVIEW



THE JOURNAL OF CLINICAL PSYCHIATRY


330 ADULT PATIENT RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY

OBJECTIVE:

This 8-week study was designed to evaluate the efficacy and safety of EnLyte/EnBrace HR as monotherapy in adults with major depressive disorder (MDD) who were also positive for at least 1 methylenetetrahydrofolate reductase (MTHFR) polymorphism associated with depression and further test the hypothesis that EnLyte/EnBrace HR will lower homocysteine in a majority of clinical responding patients.

MAY 2016

Correlation of Clinical Response With Homocysteine Reduction During Therapy With EnLyte/EnBrace HR in Patients With MDD Who Are Positive for MTHFR C677T or A 1298C Polymorphism - Andrew Farah, MD



2) 30% Reduction in Homocysteine Levels (Compared to Placebo)

NO SIDE EFFECT WAS REPORTED AT GREATER RATE
THAN PLACEBO

ONSET OF ACTION: 2 WEEKS

ENBRACE HR STUDY

www study included women with histories of MDD who were planning regnant <28 weeks. Group 1 participants were well (not in depressive episodes) and planned antidepressants for pregnancy. Group 2 participants were depressed at baseline. Primary bies included MDD relapse and depressive symptoms, verified with the Mini International is: Interview and the Montgomery-Asberg Depression Rating Scale (MADRS), respectively. folic acid metabolism and inflammation were collected.

» 1 participants (N=11; well at baseline) experienced no significant decreases in MADRS scores is of depressive relapse (27.3%; p=0.005) than expected when compared to historical controls. depressed at baseline) experienced significant improvements in MADRS scores (p=0.001), with improving >50% and one improving 33.3%. One adverse event occurred, a hospitalization for

Results suggest EnBrace HR is a well-tolerated intervention with potential efficacy for the id treatment of perinatal depression. Larger controlled trials are necessary.

uction

ssive Disorder (MDD) and Major Depressive Episodes (MDEs) in Women:

rs approximately twice as often in women compared to men. 12

gh risk for MDEs during pregnancy and the postpartum period.3

somen often discontinue standard antidepressant medications prior to or during pregnancy

few evidence-based alternatives to antidepressant medications for the treatment and prevention aring pregnancy, leaving pregnant women and clinicians with the clinical dilemma of weighing al exposure to medication against impact of untreated maternal depression.

suggests various folate forms including folic acid, folinic acid, and methylfolate may have asant effects. 3 13 These interconvertible foliate forms constitute the one-carbon cycle and are of to exert an antidepressant effect by impacting neurotransmitter synthesis. If

foliate must be converted to its active form, methylfoliate, for use in the body, polymorphisms I foliate methylation may limit the efficacy of foliate as an intervention targeting MDD. *** plate may be more readily absorbed in the brain than folate, and methylfolate has potential as a

iffoliate treatment in early trials has been found to induce significant improvement in depressive ms both when used as an adjunct to antidepressant therapy and when used as a monotherapy (5-):

elated compounds reduce rates of neural tube defects and improve child neurodevelopments. estreet corresponded require rates or neural tube defects and improve child neurodevelopmental est, conferring benefits and minimizing potential risks of antidepressants during pregnancy.^{2,2,28}

e HR is a prescription prenatal/postnatal dietary management product that contains 5.53 mg L. foliate and other foliate derivatives (1 mg folic acid, and 2.2 mg folinic acid), optimal for a population gh rates of polymorphisms that affect folic acid metabolism.

Group 1: Well at Baseline; Relapse Prevention Group

on Criteria


4DD as primary diagnosis

flanning to conceive or <28 weeks pregnant at

Group 2: Depressed at Baseline; Acute Treatment Group

Inclusion Criteria:


- MDD as primary diagnosis
- Planning to conceive or <28 weeks pregnant at



EnBrace HR For The Treatment and Prevention of Depression in Women

Trying to Conceive and During Pregnancy

Marlene P. Freeman, MD et al, Annals of Clinical Psychiatry February 2019



CONCLUSION

Study results suggest EnBrace HR is a novel and well tolerated intervention with efficacy for the prevention and treatment of depression among women planning pregnancy and who are pregnant.




Figure 1. The aim for Group 1 was to prevent depression relapse, and the aim for Group 2 was to improve depression symptoms, measured through several mood and quality of life questionnaires. Trends shown by group for the primary mood outcome measure, the MADRS (Montgomery-Asberg Depression Rating Scale) in dark blue; for secondary mood measures, the QIDS-SR (Quick Inventory of Depressive Symptomatology-Self Report) in orange and the EPDS (Edinburgh Postnatal Depression Scale) in light blue; and for a quality of life outcome, the QLESQ-SF (Quality of Life Enjoyment and Satisfaction Questionnaire -Short Form) in green. Group 1 experienced no significant changes in any of the four measures, and Group 2 experienced significant improvements in the mood questionnaires but not the quality of life questionnaire. All ANOVAs indicating significance are reported in Table 3.

PMS (Premenstrual Syndrome) Mild/Moderate

Cyclic hormonal changes of the menstrual cycle causes fluctuations of serotonin levels leading to adverse symptomology

– Mayo Clinic –

PMDD (Premenstrual Dysphoric Disorder)

Severe (DSM-5)



Tension/Anxiety, Depressed Mood – Irritability/Anger – Appetite Changes – Cravings – Insomnia – Social Conflict Withdrawal – Anhedonia – Feeling overwhelmed/ out of control - hopelessness

Biochemical Wellness

EnBrace HR normalizes serotonin levels and is an effective, all-natural, safe, root cause monotherapy option or adjunct to SSRIs, oral contraceptives, NSAIDs, and/or diuretics in the prevention or treatment of PMS/PMDD.

Dietary B Vitamin Intake and Incident of Premenstrual Syndrome. Manson et al. Am J Clin Nutr. 2011

Clinical Result Example

A 17-year-old on Paxil for PMDD experienced side effects and withdrawal symptoms after discontinuing Paxil. She was hesitant to resume antidepressant medications after presenting again with PMDD depression, and a MADRS of 20. The patient elaborated she was "putting on a happy face". She was prescribed EnBrace HR and within 4 weeks her MADRS dropped from 20 to 6.

Coenzyme Treatment of Childhood and Adolescent Depression: A Case Series. Farah et al. Clinical Psychiatry Vol 7 #5S3:93 April 2021

"For the emotional dysregulation of PMS and PMDD, we turned first-line to the natural, broad spectrum B vitamin coenzymes and mineral cofactor agent, EnBrace HR. This product has provided safe and effective relief for countless patients with these challenging symptoms"

Andrew Farah, MD
Attending Psychiatrist, Novant Health System, Winston-Salem, NC
Medical Director of Strategic Mental Health Interventions

MENOPAUSE

Declining ESTROGEN levels in MENOPAUSE aggravated by MTHFR SNP cause SEROTONIN depletion and HOMOCYSTEINE increases leading to:

EMOTIONAL DYSREGULATION

- Depression Disorders
- Anxiety
- Lack of Motivation
- Aggressiveness
- Difficulty Concentrating
- Fatigue
- Irritability

HOT FLASHES

- Insomnia
- Warmth
- Flushing
- Rapid Heartbeat
- Chills
- Headache
- Night Sweats

LOW BONE MINERAL DENSITY

- Back or Neck Pain
- Loss of Height
- Stooped Posture
- Brittle Bones/Nails
- Receding Gums
- Grip Strength
- Aching Muscles

COGNITIVE DEFICITS

- Working Memory
- Attention
- Reduced Processing Speed
- Reduced Verbal Memory
- Word Retrieval Trouble
- Loss of Train of Thought

*Clinical references available upon request

EnBrace HR restores serotonin levels and reduces high homocysteine and is clinically proven to treat adverse health outcomes in Menopause naturally and safely, alone or adjunctively with HRT, SSRIs or Calcium/D.

HOW TO PRESCRIBE



STEP 2



USE OUR ONLINE PRESCRIBER FORM

Fill in prescriber and patient information and then hit "submit"

CLICK HERE

WE WILL OFFER YOUR PATIENT THEIR FIRST BOTTLE AT A DISCOUNTED PRICE OF \$29.95

We will also provide them with the insurance steps and help determine the most cost-effective option moving forward

IF IT'S COVERED ON INSURANCE, WE WILL CONTACT YOUR OFFICE WITH PRESCRIBING INFO

If your patient does not have coverage or has a high co-pay, we will offer our discounted cash-pay option for EnBrace HR. No further action is needed for your office.